Open Access

Elevated levels of IL‑17A and IL‑35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non‑small cell lung cancer

  • Authors:
    • Yi Na Wang
    • Dan Feng Lou
    • Dan Yang Li
    • Wei Jiang
    • Jing Yin Dong
    • Wei Gao
    • Hong Chao Chen
  • View Affiliations

  • Published online on: May 13, 2020     https://doi.org/10.3892/ol.2020.11618
  • Pages: 611-622
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Advances in the immunology have identified that interleukin (IL)‑17 and IL‑35 are cytokines with diverse functions, serving important roles in autoimmune diseases and chronic inflammation. Checkpoint inhibitor pneumonitis (CIP) is focal or diffuse lung inflammation induced by immune checkpoint inhibitors and the underlying pathogenesis has not been fully explored. The aim of the present study was to investigate the roles of IL‑17A and IL‑35, and the correlation between their levels and different T cell subsets in CIP. The levels of IL‑17A and IL‑35 in peripheral blood and bronchoalveolar lavage fluid (BALF) were measured in patients with non‑small cell lung cancer (NSCLC) with CIP, and the corresponding controls. The percentages of helper T lymphocyte (Th)1, Th2 and Th17 cells, and regulatory T cells (Tregs) in the peripheral blood were synchronically detected. Serum levels of IL‑17A and IL‑35 were significantly increased at the time of CIP diagnosis compared with the baseline, and significantly decreased upon clinical recovery or improvement. IL‑17A and IL‑35 were also increased in the BALF during the development of CIP compared with the baseline. Serum levels of IL‑17A were positively correlated with the percentages of Th1 and Th17 cells as well as the ratio of Th17 to Tregs, but negatively associated with the frequency of Tregs in CIP. Serum levels of IL‑35 were positively correlated with the percentages of Th1 and Tregs, and with the ratio of Th1 to Th2 cells in CIP. A higher frequency of Th1 and Th17 cells, as well as higher ratios of Th17 to Tregs and Th1 to Th2 cells were detected upon development of CIP comparing with the baseline. These data suggested that the activation of Th1 and Th17 cells, as well as Treg inhibition contributed to the imbalanced ratios of Th1 to Th2 and Th17 to Tregs, which resulted in increased secretion of IL‑17A and IL‑35 in the plasma and BALF; this may present a valuable index to monitor the development and severity of CIP in patients with NSCLC receiving immunotherapy.
View Figures
View References

Related Articles

Journal Cover

July-2020
Volume 20 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang YN, Lou DF, Li DY, Jiang W, Dong JY, Gao W and Chen HC: Elevated levels of IL‑17A and IL‑35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non‑small cell lung cancer . Oncol Lett 20: 611-622, 2020
APA
Wang, Y.N., Lou, D.F., Li, D.Y., Jiang, W., Dong, J.Y., Gao, W., & Chen, H.C. (2020). Elevated levels of IL‑17A and IL‑35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non‑small cell lung cancer . Oncology Letters, 20, 611-622. https://doi.org/10.3892/ol.2020.11618
MLA
Wang, Y. N., Lou, D. F., Li, D. Y., Jiang, W., Dong, J. Y., Gao, W., Chen, H. C."Elevated levels of IL‑17A and IL‑35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non‑small cell lung cancer ". Oncology Letters 20.1 (2020): 611-622.
Chicago
Wang, Y. N., Lou, D. F., Li, D. Y., Jiang, W., Dong, J. Y., Gao, W., Chen, H. C."Elevated levels of IL‑17A and IL‑35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non‑small cell lung cancer ". Oncology Letters 20, no. 1 (2020): 611-622. https://doi.org/10.3892/ol.2020.11618